D A Krieger1, P A Hudgins2, G K Nayak3, K L Baugnon2, A S Corey2, M R Patel4, J J Beitler4,5,6, N F Saba6, Y Liu7, A H Aiken8. 1. From the Department of Radiology, Hackensack University Medical Center (D.A.K.), Hackensack, New Jersey. 2. Departments of Radiology and Imaging Sciences (P.A.H., A.H.A., K.L.B., A.S.C.). 3. Department of Radiology (G.K.N.), New York University School of Medicine, New York, New York. 4. Otolaryngology Head and Neck Surgery (M.R.P., J.J.B.), Emory University School of Medicine, Atlanta, Georgia. 5. Departments of Radiation Oncology (J.J.B.). 6. Hematology and Medical Oncology (J.J.B., N.F.S.). 7. Biostatistics (Y.L.), Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia. 8. Departments of Radiology and Imaging Sciences (P.A.H., A.H.A., K.L.B., A.S.C.) Ashley.aiken@emoryhealthcare.org.
Abstract
BACKGROUND AND PURPOSE: The Head and Neck Imaging Reporting and Data System (NI-RADS) surveillance template for head and neck cancer includes a numeric assessment of suspicion for recurrence (1-4) for the primary site and neck. Category 1 indicates no evidence of recurrence; category 2, low suspicion of recurrence; category 3, high suspicion of recurrence; and category 4, known recurrence. Our purpose was to evaluate the performance of the NI-RADS scoring system to predict local and regional disease recurrence or persistence. MATERIALS AND METHODS: This study was classified as a quality-improvement project by the institutional review board. A retrospective database search yielded 500 consecutive cases interpreted using the NI-RADS template. Cases without a numeric score, non-squamous cell carcinoma primary tumors, and primary squamous cell carcinoma outside the head and neck were excluded. The electronic medical record was reviewed to determine the subsequent management, pathology results, and outcome of clinical and radiologic follow-up. RESULTS: A total of 318 scans and 618 targets (314 primary targets and 304 nodal targets) met the inclusion criteria. Among the 618 targets, 85.4% were scored NI-RADS 1; 9.4% were scored NI-RADS 2; and 5.2% were scored NI-RADS 3. The rates of positive disease were 3.79%, 17.2%, and 59.4% for each NI-RADS category, respectively. Univariate association analysis demonstrated a strong association between the NI-RADS score and ultimate disease recurrence, with P < .001 for primary and regional sites. CONCLUSIONS: The baseline performance of NI-RADS was good, demonstrating significant discrimination among the categories 1-3 for predicting disease.
BACKGROUND AND PURPOSE: The Head and Neck Imaging Reporting and Data System (NI-RADS) surveillance template for head and neck cancer includes a numeric assessment of suspicion for recurrence (1-4) for the primary site and neck. Category 1 indicates no evidence of recurrence; category 2, low suspicion of recurrence; category 3, high suspicion of recurrence; and category 4, known recurrence. Our purpose was to evaluate the performance of the NI-RADS scoring system to predict local and regional disease recurrence or persistence. MATERIALS AND METHODS: This study was classified as a quality-improvement project by the institutional review board. A retrospective database search yielded 500 consecutive cases interpreted using the NI-RADS template. Cases without a numeric score, non-squamous cell carcinoma primary tumors, and primary squamous cell carcinoma outside the head and neck were excluded. The electronic medical record was reviewed to determine the subsequent management, pathology results, and outcome of clinical and radiologic follow-up. RESULTS: A total of 318 scans and 618 targets (314 primary targets and 304 nodal targets) met the inclusion criteria. Among the 618 targets, 85.4% were scored NI-RADS 1; 9.4% were scored NI-RADS 2; and 5.2% were scored NI-RADS 3. The rates of positive disease were 3.79%, 17.2%, and 59.4% for each NI-RADS category, respectively. Univariate association analysis demonstrated a strong association between the NI-RADS score and ultimate disease recurrence, with P < .001 for primary and regional sites. CONCLUSIONS: The baseline performance of NI-RADS was good, demonstrating significant discrimination among the categories 1-3 for predicting disease.
Authors: Ashley H Aiken; April Farley; Kristen L Baugnon; Amanda Corey; Mark El-Deiry; Richard Duszak; Jonathan Beitler; Patricia A Hudgins Journal: J Am Coll Radiol Date: 2015-11-11 Impact factor: 5.532
Authors: David G Pfister; Sharon Spencer; David M Brizel; Barbara Burtness; Paul M Busse; Jimmy J Caudell; Anthony J Cmelak; A Dimitrios Colevas; Frank Dunphy; David W Eisele; Jill Gilbert; Maura L Gillison; Robert I Haddad; Bruce H Haughey; Wesley L Hicks; Ying J Hitchcock; Antonio Jimeno; Merrill S Kies; William M Lydiatt; Ellie Maghami; Renato Martins; Thomas McCaffrey; Loren K Mell; Bharat B Mittal; Harlan A Pinto; John A Ridge; Cristina P Rodriguez; Sandeep Samant; David E Schuller; Jatin P Shah; Randal S Weber; Gregory T Wolf; Frank Worden; Sue S Yom; Nicole R McMillian; Miranda Hughes Journal: J Natl Compr Canc Netw Date: 2014-10 Impact factor: 11.908
Authors: Benjamin R Roman; Snehal G Patel; Marilene B Wang; Anna M Pou; F Christopher Holsinger; David Myssiorek; David Goldenberg; Samuel Swisher-McClure; Alexander Lin; Jatin P Shah; Judy A Shea Journal: J Natl Compr Canc Netw Date: 2015-01 Impact factor: 11.908
Authors: Allen S Ho; Gabriel J Tsao; Frank W Chen; Tianjie Shen; Michael J Kaplan; A Dimitrios Colevas; Nancy J Fischbein; Andrew Quon; Quynh-Thu Le; Harlan A Pinto; Willard E Fee; John B Sunwoo; Davud Sirjani; Wendy Hara; Mike Yao Journal: Cancer Date: 2012-12-07 Impact factor: 6.860
Authors: Seng Chuan Ong; Heiko Schöder; Nancy Y Lee; Snehal G Patel; Diane Carlson; Matthew Fury; David G Pfister; Jatin P Shah; Steven M Larson; Dennis H Kraus Journal: J Nucl Med Date: 2008-03-14 Impact factor: 10.057
Authors: M McDermott; M Hughes; T Rath; J T Johnson; D E Heron; G J Kubicek; S W Kim; R L Ferris; U Duvvuri; J P Ohr; B F Branstetter Journal: AJNR Am J Neuroradiol Date: 2013-05-02 Impact factor: 3.825
Authors: A Gore; K Baugnon; J Beitler; N F Saba; M R Patel; X Wu; B J Boyce; A H Aiken Journal: AJNR Am J Neuroradiol Date: 2020-06-18 Impact factor: 3.825
Authors: F H J Elsholtz; S-R Ro; S Shnayien; C Erxleben; H-C Bauknecht; J Lenk; L-A Schaafs; B Hamm; S M Niehues Journal: AJNR Am J Neuroradiol Date: 2020-04-23 Impact factor: 3.825
Authors: L D Patel; K Bridgham; J Ciriello; R Almardawi; J Leon; J Hostetter; S Yazbek; P Raghavan Journal: AJNR Am J Neuroradiol Date: 2022-02-17 Impact factor: 3.825
Authors: A Jajodia; G Mandal; V Yadav; J Khoda; J Goyal; S Pasricha; S Puri; A Dewan Journal: AJNR Am J Neuroradiol Date: 2022-06-23 Impact factor: 4.966
Authors: Zachary Patel; Jennifer A Schroeder; Paul M Bunch; Joni K Evans; Cole R Steber; Adam G Johnson; Joshua C Farris; Ryan T Hughes Journal: JAMA Otolaryngol Head Neck Surg Date: 2022-10-01 Impact factor: 8.961
Authors: P Wangaryattawanich; B F Branstetter; J D Ly; U Duvvuri; D E Heron; T J Rath Journal: AJNR Am J Neuroradiol Date: 2020-05-28 Impact factor: 3.825